Coya Therapeutics: This BioPharma Company Has Some Big News To Share

Howard Burman, Ph.D, CEO & Chairman of Coya Therapeutics Inc COYA, was a guest on Benzinga’s All Access.

Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. The company is currently developing multi-modality Treg therapies for neurodegenerative, autoimmune and metabolic diseases.

Coya has recently announced positive data from recent and ongoing trials.

Watch the full interview here:

Featured photo by Hal Gatewood on Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksInterviewGeneralCoya Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!